Zura Bio

Developing novel medicines for serious immune system disorders

Dual Pathway Approach to Improve Patient Outcomes: The autoimmune space is plagued with clinical failures of biologics targeting single pathways in complex diseases driven by multiple pathways. Zura is developing a pipeline of novel dual-pathway antibodies addressing validated disease drivers that have potential to improve outcomes and restore hope for those burdened by autoimmune diseases.
First-in-Class Treatment for Systemic Sclerosis (SSc): SSc, a rare and life-threatening autoimmune disease characterized by tissue inflammation and fibrosis, has been a challenging indication for drug development. Zura is advancing tibulizumab, a “four-headed hammer” dual agonist of IL-17 and BAFF to address both pathways which are known drivers of SSc. A potentially first-in-class treatment for SSc, tibulizumab is a fusion of FDA approved TALZ® and clinically validated tabalumab, with potential for broader efficacy and a more convenient dosing regimen than existing approaches.
Key Events in 2025: Initiation of Phase 2 study of tibulizumab in SSc in Q4-2024; Initial indication selection for a Phase 2 clinical study of crebankitug expected by the end of 2024; Initiation of Phase 2 study of tibulizumab in HS in Q2-2025